Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.50 |
| ▸ | HTR2A | P28223 | 17/20 | 0.50 |
| ▸ | DRD3 | P35462 | 17/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269249 | 0.90 | HTR2C (0.47) | DRD2HTR2ADRD3HTR2C | |
| SCHEMBL1727503 | 0.84 | DRD2 (0.56) | DRD2HTR2ADRD3HTR2CSIRT2 | |
| SCHEMBL3270079 | 0.83 | SIRT2 (0.49) | DRD2HTR2CSIRT2SIRT1SIRT3 | |
| SCHEMBL3266163 | 0.80 | SIRT2 (0.44) | SIRT2SIRT1SIRT3 | |
| SCHEMBL238082 | 0.80 | SIRT2 (0.49) | SIRT2SIRT1SIRT3 | |
| SCHEMBL3265661 | 0.79 | SIRT2 (0.49) | DRD2SIRT2SIRT1SIRT3 | |
| SCHEMBL3265672 | 0.78 | CHRM4 (0.45) | DRD2SIRT2SIRT1SIRT3 | |
| SCHEMBL3269140 | 0.78 | KDM4E (0.57) | DRD2HTR2ASIRT2SIRT1SIRT3 | |
| SCHEMBL3266253 | 0.77 | SIRT2 (0.48) | DRD2HTR2ADRD3HTR2CSIRT2 | |
| SCHEMBL3269154 | 0.76 | HTR1A (0.43) | DRD2SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DRD2 1223/4885HTR2A 2607/4885DRD3 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.